Listen in the Podli app 🎧
Follow your favourite podcasts, listen offline and in the car with CarPlay and Android Auto, and always pick up where you left off. Free to try.
Featuring an interview with Prof Karim Fizazi, including the following topics:
- Perspectives on the PROTEUS Phase III trial evaluating the addition of apalutamide to standard therapy for high-risk localized prostate cancer (0:00)
- Mechanism of action of opevesostat and potential role in castration-resistant prostate cancer with androgen receptor mutations (15:37)
- Perspectives on alpha- and beta-emitting radiopharmaceuticals in the treatment of prostate cancer (22:47)
- Novel antibody-drug conjugates and proteolysis-targeting chimeras (30:43)
- Treatment approaches for metastatic hormone-sensitive prostate cancer — de novo symptomatic presentation versus PSMA-only metastatic recurrence after local therapy (34:51)
- Role of intermittent therapy in the treatment of prostate cancer (38:48)
- Treatment intensification approaches in prostate cancer (41:38)
- Case: A man in his late 60s with de novo PSMA PET-positive metastatic castration-sensitive prostate cancer (45:25)
CME information and select publications
